GlobeNewswire by notified

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Share

Company Announcement

COPENHAGEN, Denmark; November 21, 2022Genmab A/S (Nasdaq:GMAB) announced today that the Board decided to grant 11,608restricted stock units to members of the Board of Directors and employees of the Company as well as the Company’s subsidiaries and9,057warrants to employees of the Company and the Company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 3,172. 

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted stock units.  

The exercise price for each warrant is DKK 3,172. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 1,123.15. 

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants. 

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.


Company Announcement no. 58
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules2.12.2022 07:55:00 CET | Press release

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "TAKEOVER RULES"). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DECEMBER 2, 2022 Statement from Sanofi regarding: rule 2.12 of the takeover rules Paris, December 2, 2022. As required by Rule 2.12 of the Takeover Rules, Sanofi S.A. (“Sanofi”) confirms that any offer for Horizon Therapeutics plc, if made by Sanofi, will be solely in cash. There is no certainty that any offer will be made, nor as to the terms on which any such offer may be made, if forthcoming. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible

Sampo plc’s share buybacks 01/12/20222.12.2022 07:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 02/12/2022 at 08:30 am Sampo plc’s share buybacks 01/12/2022 On 01/12/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,22948.68AQEU31,99648.68CEUX13,98448.68TQEX59,79148.64XHELTOTAL120,00048.66 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 16,801,839 Sampo A shares representing 3.15 per cent of the total number of shares in Sampo plc. Details of

AB Linas Agro Group investors calendar for the 20232.12.2022 07:30:00 CET | Press release

A list of key information disclosure dates in 2023: February 28, 2023Interim half-year unaudited report for FY 2022/2023.March 1, 2023Investor Conference Webinar to introduce unaudited financial and activity results for the half-year of FY 2022/2023.May 31, 2023Interim unaudited report for 9 months of FY 2022/2023.June 1, 2023Investor Conference Webinar to introduce unaudited financial and activity results for 9 months of FY 2022/2023.August 31, 2023Interim unaudited report for 12 months of FY 2022/2023.September 4, 2023Investor Conference Webinar to introduce unaudited financial and activity results for 12 months of FY 2022/2023.Week 40 (Oct 2-6, 2023)Notice on Annual General Meeting of shareholders.Week 43 (Oct 23-27, 2023)Resolutions of the Annual General Meeting of shareholders and Annual audited results for FY 2022/2023.November 30, 2023Interim unaudited report for 3 months of 2023/2024 financial year.December 1, 2023Investor Conference Webinar to introduce unaudited financial and

Arcadis completes the acquisition of DPS Group, creating a leading position in the Life Sciences and Semiconductor manufacturing market2.12.2022 07:00:00 CET | Press release

Arcadis completes the acquisition of DPS Group, creating a leading position in the Life Sciences and Semiconductor manufacturing market Creates a full-service advisory for high-tech industrial manufacturing clients, combining DPS Group’s (DPS) and Arcadis’ complementary service offeringsDPS’s high growth and resilient Life Sciences and Semiconductor manufacturing expertise will become part of Arcadis’ Places Global Business Area (GBA)Arcadis adds an extra 2,850 talented employees to its growing business, increasing headcount by over 20% to 36,000 since the beginning of 2022Arcadis’ Simon Bimpson to lead Arcadis DPS Group, and current DPS’ Chief Executive, Frank Keogh to take on the role of strategic advisor Amsterdam, 2 December 2022 – Arcadis, the leading global design & consultancy organization for natural and built assets has today announced it has completed the acquisition of DPS, a leading consultancy, engineering and construction management company for Life Sciences and Semicondu

Mandalay Resources Corporation Announces Refinancing of Credit Facility2.12.2022 02:26:55 CET | Press release

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) is pleased to announce that it has entered into a credit agreement with The Bank of Nova Scotia (“Scotiabank”) providing for a senior secured revolving credit facility in an aggregate amount of up to US$35 million (the “Revolving Credit Facility”). The initial drawdown under the Revolving Credit Facility will be used to repay the Company’s existing syndicated facility with HSBC Bank Canada and Macquarie Bank Limited (the “Existing Facility”) which had US$32.6 million outstanding before repayment. The residual proceeds from the Revolving Credit Facility will be used for general corporate and working capital purposes. The hedge arrangements entered into in connection with the Existing Facility will remain in place until their expiry in June 2023. The Revolving Credit Facility